JTZ-951 + lapatinib

JTZ-951 + lapatinib is a **combination drug** composed of JTZ-951 and lapatinib. Lapatinib is a **small molecule tyrosine kinase inhibitor** targeting the intracellular kinase domains of **epidermal growth factor receptor (EGFR/HER1/ERBB1)** and **human epidermal growth factor receptor type 2 (HER2/ERBB2)**, thereby blocking downstream signaling pathways related to tumor growth and proliferation. Lapatinib is an FDA-approved anti-cancer medication developed primarily for HER2-positive breast cancer, with demonstrated efficacy when combined with other therapies such as capecitabine or letrozole. JTZ-951's properties, mechanism, and regulatory status could not be found in the available data; its pairing with lapatinib suggests development for oncologic use, most likely in solid tumors. Lapatinib is developed by GlaxoSmithKline (GSK).

Other names

lapatinib ditosylatelapatinib ditosylate monohydratelapatinib tosylateGW572016GW-572016GW 572016JTZ-951JTZ951JTZ 951